CGM metrics predict risk for stage 3 type 1 diabetes better than patient characteristics

Continuous glucose monitoring (CGM) metrics can predict imminent stage 3 type 1 diabetes for individuals who are islet autoantibody positive. A study compared predictive models using data from five study groups and found that CGM metrics alone outperformed baseline characteristics for predicting type 1 diabetes risk. Combining patient characteristics with CGM metrics provided the best prediction. The study also classified participants into low, medium, and high-risk groups based on their characteristics and CGM metrics. More research is needed to further understand the relationship between CGM metrics and type 1 diabetes progression, including the use of CGM in preventing complications and its potential as an alternative to oral glucose tolerance tests.

Source link

error: Content is protected !!